SmartHarvest Portfolios LLC Takes $564,000 Position in Haleon PLC Sponsored ADR $HLN

SmartHarvest Portfolios LLC acquired a new position in shares of Haleon PLC Sponsored ADR (NYSE:HLN) in the 4th quarter, according to the company in its most recent filing with the SEC. The fund acquired 55,820 shares of the company’s stock, valued at approximately $564,000.

A number of other hedge funds and other institutional investors also recently bought and sold shares of HLN. Brighton Jones LLC acquired a new position in shares of Haleon during the fourth quarter worth $187,000. AQR Capital Management LLC boosted its position in shares of Haleon by 22.5% in the 1st quarter. AQR Capital Management LLC now owns 96,323 shares of the company’s stock worth $991,000 after purchasing an additional 17,720 shares in the last quarter. Focus Partners Wealth grew its stake in Haleon by 7.6% during the 1st quarter. Focus Partners Wealth now owns 73,106 shares of the company’s stock worth $752,000 after buying an additional 5,178 shares during the last quarter. Geneos Wealth Management Inc. grew its stake in Haleon by 33.0% during the 1st quarter. Geneos Wealth Management Inc. now owns 4,846 shares of the company’s stock worth $50,000 after buying an additional 1,203 shares during the last quarter. Finally, CW Advisors LLC increased its position in Haleon by 11.6% during the 2nd quarter. CW Advisors LLC now owns 25,075 shares of the company’s stock valued at $260,000 after buying an additional 2,601 shares in the last quarter. Hedge funds and other institutional investors own 6.67% of the company’s stock.

Haleon Price Performance

NYSE HLN opened at $9.05 on Friday. The company has a market cap of $40.06 billion, a price-to-earnings ratio of 23.19, a PEG ratio of 2.07 and a beta of 0.13. The company has a debt-to-equity ratio of 0.47, a current ratio of 0.92 and a quick ratio of 0.71. The stock’s fifty day moving average price is $9.36 and its 200 day moving average price is $9.91. Haleon PLC Sponsored ADR has a 1 year low of $8.65 and a 1 year high of $11.28.

Haleon (NYSE:HLN) last posted its quarterly earnings results on Saturday, February 14th. The company reported $6.32 earnings per share for the quarter. The firm had revenue of $3.65 billion for the quarter. As a group, equities research analysts forecast that Haleon PLC Sponsored ADR will post 0.56 earnings per share for the current year.

Analyst Upgrades and Downgrades

Several brokerages have weighed in on HLN. Wall Street Zen raised Haleon from a “hold” rating to a “buy” rating in a report on Saturday, March 21st. Argus raised shares of Haleon to a “strong-buy” rating in a research report on Tuesday, March 17th. Finally, Deutsche Bank Aktiengesellschaft reiterated a “sell” rating on shares of Haleon in a research note on Thursday, April 30th. Two equities research analysts have rated the stock with a Strong Buy rating, three have given a Buy rating, two have assigned a Hold rating and one has assigned a Sell rating to the company. Based on data from MarketBeat.com, Haleon currently has a consensus rating of “Moderate Buy”.

About Haleon

Haleon plc (NYSE:HLN) is a global consumer healthcare company formed through the separation of a large pharmaceutical group’s consumer health business in 2022. Headquartered in the United Kingdom, Haleon develops, manufactures and markets a broad portfolio of over‑the‑counter medicines, oral health products, vitamins, minerals and supplements, and other consumer health goods designed for daily self‑care and symptom relief.

The company’s product mix spans categories such as oral care (toothpastes and sensitivity treatments), pain relief and analgesics, respiratory remedies, digestive health products, topical treatments and nutritional supplements.